Protagonist (PTGX) is a high-conviction buy: late-stage icotrokinra & rusfertide near 2026 milestones, strong cash runway. Read more here.

An updated edition of the December 16, 2025, article. An aging U.S. population is becoming a first-order driver of consumption reallocation. Going by the data from the United States Census Bureau, by ...

With training and planning, self-injecting your rheumatoid arthritis medication may be easier than you think.

AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo. | AstraZeneca will have to negotiate what ...

A bill introduced in early 2026 would've authorized executions by suffocation via nitrogen gas.

AstraZeneca has already provided the requested information to the FDA and a decision on the updated BLA is expected in the first half of 2026.

Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 weeks, according to data published in Arthritis & Rheumatology.“As a ...

Iowa and Indiana have recently introduced legislation that would establish new registration and licensure requirements for medical spas. Iowa ...

The FDA is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab).

New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime insulin to improve glycemic control.